Sagimet Biosciences (SGMT) Total Current Liabilities (2022 - 2026)

Sagimet Biosciences' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.1 million, up 14.53% from the prior year.
• Total Current Liabilities climbed to $5.3 million in Q1 2026 per SGMT's latest filing, from $5.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $9.1 million in Q3 2025 and bottomed at $4.5 million in Q4 2024.
• The 5-year median for Total Current Liabilities is $5.3 million (2023), against an average of $5.8 million.
• Across the five-year window, Total Current Liabilities decreased 21.22% in 2024 and advanced 14.53% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $5.3 million in 2022, then grew by 7.1% to $5.7 million in 2023, then dropped by 21.22% to $4.5 million in 2024, then advanced by 14.53% to $5.1 million in 2025, then gained by 3.84% to $5.3 million in 2026.
• Per Business Quant, the three latest SGMT Total Current Liabilities figures stand at $5.3 million (Q1 2026), $5.1 million (Q4 2025), and $9.1 million (Q3 2025).